Current Status of Baricitinib as a Repurposed Therapy for COVID-19

Current Status of Baricitinib as a Repurposed Therapy for COVID-19

The emergence of the COVID-19 pandemic has mandated the instant (re)search for potential drug candidates. In response to the unprecedented situation, it was recognized early that repurposing of available drugs in the market could timely save lives, by skipping the lengthy phases of preclinical and i...

Full description

Bibliographic Details
Main Authors: Maha Saber-Ayad, Sarah Hammoudeh, Eman Abu-Gharbieh, Rifat Hamoudi, Hamadeh Tarazi, Taleb H. Al-Tel, Qutayba Hamid
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Pharmaceuticals
Subjects:
bioinformatics
transcriptomics
gene expression
baricitinib
JAK inhibitors
COVID-19
Online Access:https://www.mdpi.com/1424-8247/14/7/680

Internet

https://www.mdpi.com/1424-8247/14/7/680

Similar Items